AustralieFrV1, PascalFrancis, Curation, bibRecord, 002E11

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

Identifieur interne : 002E11 ( PascalFrancis/Curation ); précédent : 002E10; suivant : 002E12

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

Auteurs : Paul D. Miller [États-Unis] ; Pierre D. Delmas [France] ; Robert Lindsay [États-Unis] ; Nelson B. Watts [États-Unis] ; Marjorie Luckey [États-Unis] ; Jonathan Adachi [Canada] ; Kenneth Saag [États-Unis] ; Susan L. Greenspan [États-Unis] ; Ego Seeman [Australie] ; Steven Boonen [Belgique] ; Suzanne Meeves [États-Unis] ; Thomas F. Lang [États-Unis] ; John P. Bilezikian [États-Unis]

Source :

The Journal of clinical endocrinology and metabolism [ 0021-972X ] ; 2008.

RBID : Pascal:08-0499193

Descripteurs français

Pascal (Inist)
- Ostéoporose, Précoce, Homme, Tériparatide, Femelle, Femme, Acide alendronique, Adulte, Traitement, Acide risédronique, Endocrinologie, Maladie métabolique, Nutrition, Obésité, Antiostéoporotique, Antirésorptif, Etat nutritionnel.
Wicri :
- topic : Homme, Femme, Adulte, Nutrition.

English descriptors

KwdEn :
- Adult, Alendronic acid, Antiosteoporotic, Antiresorptive agent, Early, Endocrinology, Female, Human, Metabolic diseases, Nutrition, Nutritional status, Obesity, Osteoporosis, Risedronic acid, Teriparatide, Treatment, Woman.

Abstract

Background: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. Methods: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early changes in bone turnover markers and 12-month areal and volumetric BMD. Results: In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean ± SE, 86.0 ± 5.6 vs. 61.2 ± 5.3 ng/ml, respectively; P < 0.001). Findings were similar for the other bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05). Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45). Teriparatide was well tolerated. Conclusion: This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure.

A01	`01`	`1`		`@0 0021-972X`
A02	`01`			`@0 JCEMAZ`
A03		`1`		`@0 J. clin. endocrinol. metab.`
A05				`@2 93`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate`
A11	`01`	`1`		`@1 MILLER (Paul D.)`
A11	`02`	`1`		`@1 DELMAS (Pierre D.)`
A11	`03`	`1`		`@1 LINDSAY (Robert)`
A11	`04`	`1`		`@1 WATTS (Nelson B.)`
A11	`05`	`1`		`@1 LUCKEY (Marjorie)`
A11	`06`	`1`		`@1 ADACHI (Jonathan)`
A11	`07`	`1`		`@1 SAAG (Kenneth)`
A11	`08`	`1`		`@1 GREENSPAN (Susan L.)`
A11	`09`	`1`		`@1 SEEMAN (Ego)`
A11	`10`	`1`		`@1 BOONEN (Steven)`
A11	`11`	`1`		`@1 MEEVES (Suzanne)`
A11	`12`	`1`		`@1 LANG (Thomas F.)`
A11	`13`	`1`		`@1 BILEZIKIAN (John P.)`
A14	`01`			`@1 Colorado Center for Bone Research @2 Lakewood, Colorado 80227 @3 USA @Z 1 aut.`
A14	`02`			`@1 Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Claude Bernard University Lyon 1 @2 69372 Lyon @3 FRA @Z 2 aut.`
A14	`03`			`@1 Regional Bone Center Helen Hayes Hospital @2 West Haverstraw, New York 10993 @3 USA @Z 3 aut.`
A14	`04`			`@1 University of Cincinnati Bone Health and Osteoporosis Center @2 Cincinnati, Ohio 45219 @3 USA @Z 4 aut.`
A14	`05`			`@1 St. Barnabas Osteoporosis Center @2 Livingston, New Jersey 07039 @3 USA @Z 5 aut.`
A14	`06`			`@1 St. Joseph's Healthcare McMaster University @2 Hamilton, Ontario, L8S4L8 @3 CAN @Z 6 aut.`
A14	`07`			`@1 Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham @2 Birmingham, Alabama 35233 @3 USA @Z 7 aut.`
A14	`08`			`@1 University of Pittsburgh Medical Center @2 Pittsburgh, Pennsylvania 15213 @3 USA @Z 8 aut.`
A14	`09`			`@1 Endocrinology Department Austin Health, University of Melbourne @2 Victoria 3010 @3 AUS @Z 9 aut.`
A14	`10`			`@1 Bone Research Unit Leuven University, Department of Experimental Medicine @2 3000 Leuven @3 BEL @Z 10 aut.`
A14	`11`			`@1 Sanofi-aventis @2 Bridgewater, New Jersey 08807 @3 USA @Z 11 aut.`
A14	`12`			`@1 Department of Radiology Center for Molecular and Functional Imaging, University of California at San Francisco @2 San Francisco, California 94107 @3 USA @Z 12 aut.`
A14	`13`			`@1 Division of Endocrinology Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons @2 New York, New York 10021 @3 USA @Z 13 aut.`
A17	`01`	`1`		`@1 Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators @3 INC`
A20				`@1 3785-3793`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6022 @5 354000184256870180`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 08-0499193`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Journal of clinical endocrinology and metabolism`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. Methods: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early changes in bone turnover markers and 12-month areal and volumetric BMD. Results: In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean ± SE, 86.0 ± 5.6 vs. 61.2 ± 5.3 ng/ml, respectively; P < 0.001). Findings were similar for the other bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05). Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45). Teriparatide was well tolerated. Conclusion: This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure.
C02	`01`	`X`		`@0 002A16E`
C02	`02`	`X`		`@0 002A28`
C02	`03`	`X`		`@0 002B21`
C03	`01`	`X`	`FRE`	`@0 Ostéoporose @5 01`
C03	`01`	`X`	`ENG`	`@0 Osteoporosis @5 01`
C03	`01`	`X`	`SPA`	`@0 Osteoporosis @5 01`
C03	`02`	`X`	`FRE`	`@0 Précoce @5 02`
C03	`02`	`X`	`ENG`	`@0 Early @5 02`
C03	`02`	`X`	`SPA`	`@0 Precoz @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Tériparatide @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Teriparatide @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Teriparatida @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Femelle @5 05`
C03	`05`	`X`	`ENG`	`@0 Female @5 05`
C03	`05`	`X`	`SPA`	`@0 Hembra @5 05`
C03	`06`	`X`	`FRE`	`@0 Femme @5 06`
C03	`06`	`X`	`ENG`	`@0 Woman @5 06`
C03	`06`	`X`	`SPA`	`@0 Mujer @5 06`
C03	`07`	`X`	`FRE`	`@0 Acide alendronique @2 NK @2 FR @5 07`
C03	`07`	`X`	`ENG`	`@0 Alendronic acid @2 NK @2 FR @5 07`
C03	`07`	`X`	`SPA`	`@0 Acido alendrónico @2 NK @2 FR @5 07`
C03	`08`	`X`	`FRE`	`@0 Adulte @5 08`
C03	`08`	`X`	`ENG`	`@0 Adult @5 08`
C03	`08`	`X`	`SPA`	`@0 Adulto @5 08`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`10`	`X`	`FRE`	`@0 Acide risédronique @2 NK @2 FR @5 10`
C03	`10`	`X`	`ENG`	`@0 Risedronic acid @2 NK @2 FR @5 10`
C03	`10`	`X`	`SPA`	`@0 Acido risedrónico @2 NK @2 FR @5 10`
C03	`11`	`X`	`FRE`	`@0 Endocrinologie @5 11`
C03	`11`	`X`	`ENG`	`@0 Endocrinology @5 11`
C03	`11`	`X`	`SPA`	`@0 Endocrinología @5 11`
C03	`12`	`X`	`FRE`	`@0 Maladie métabolique @5 12`
C03	`12`	`X`	`ENG`	`@0 Metabolic diseases @5 12`
C03	`12`	`X`	`SPA`	`@0 Metabolismo patología @5 12`
C03	`13`	`X`	`FRE`	`@0 Nutrition @5 17`
C03	`13`	`X`	`ENG`	`@0 Nutrition @5 17`
C03	`13`	`X`	`SPA`	`@0 Nutrición @5 17`
C03	`14`	`X`	`FRE`	`@0 Obésité @5 18`
C03	`14`	`X`	`ENG`	`@0 Obesity @5 18`
C03	`14`	`X`	`SPA`	`@0 Obesidad @5 18`
C03	`15`	`X`	`FRE`	`@0 Antiostéoporotique @5 25`
C03	`15`	`X`	`ENG`	`@0 Antiosteoporotic @5 25`
C03	`15`	`X`	`SPA`	`@0 Antiosteoporótico @5 25`
C03	`16`	`X`	`FRE`	`@0 Antirésorptif @5 26`
C03	`16`	`X`	`ENG`	`@0 Antiresorptive agent @5 26`
C03	`16`	`X`	`SPA`	`@0 Antirresortivo @5 26`
C03	`17`	`X`	`FRE`	`@0 Etat nutritionnel @5 27`
C03	`17`	`X`	`ENG`	`@0 Nutritional status @5 27`
C03	`17`	`X`	`SPA`	`@0 Estado nutricional @5 27`
C07	`01`	`X`	`FRE`	`@0 Pathologie du système ostéoarticulaire @5 37`
C07	`01`	`X`	`ENG`	`@0 Diseases of the osteoarticular system @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema osteoarticular patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Ostéoformateur @5 38`
C07	`02`	`X`	`ENG`	`@0 Osteoforming @5 38`
C07	`02`	`X`	`SPA`	`@0 Osteoformador @5 38`
C07	`03`	`X`	`FRE`	`@0 Bisphosphonates @5 39`
C07	`03`	`X`	`ENG`	`@0 Bisphosphonates @5 39`
C07	`03`	`X`	`SPA`	`@0 Bisfosfonatos @5 39`
C07	`04`	`X`	`FRE`	`@0 Dérivé de l'acide diphosphonique @5 40`
C07	`04`	`X`	`ENG`	`@0 Diphosphonic acid derivatives @5 40`
C07	`04`	`X`	`SPA`	`@0 Difosfonico ácido derivado @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble de la nutrition @5 41`
C07	`05`	`X`	`ENG`	`@0 Nutrition disorder @5 41`
C07	`05`	`X`	`SPA`	`@0 Trastorno nutricíon @5 41`
N21				`@1 329`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003242

Links to Exploration step

Pascal:08-0499193

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate</title>
<author><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Colorado Center for Bone Research</s1>
<s2>Lakewood, Colorado 80227</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Claude Bernard University Lyon 1</s1>
<s2>69372 Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Regional Bone Center Helen Hayes Hospital</s1>
<s2>West Haverstraw, New York 10993</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Cincinnati Bone Health and Osteoporosis Center</s1>
<s2>Cincinnati, Ohio 45219</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>St. Barnabas Osteoporosis Center</s1>
<s2>Livingston, New Jersey 07039</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>St. Joseph's Healthcare McMaster University</s1>
<s2>Hamilton, Ontario, L8S4L8</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama 35233</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, Pennsylvania 15213</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Endocrinology Department Austin Health, University of Melbourne</s1>
<s2>Victoria 3010</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Bone Research Unit Leuven University, Department of Experimental Medicine</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sanofi-aventis</s1>
<s2>Bridgewater, New Jersey 08807</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Radiology Center for Molecular and Functional Imaging, University of California at San Francisco</s1>
<s2>San Francisco, California 94107</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Endocrinology Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons</s1>
<s2>New York, New York 10021</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0499193</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0499193 INIST</idno>
<idno type="RBID">Pascal:08-0499193</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003242</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002E11</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate</title>
<author><name sortKey="Miller, Paul D" sort="Miller, Paul D" uniqKey="Miller P" first="Paul D." last="Miller">Paul D. Miller</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Colorado Center for Bone Research</s1>
<s2>Lakewood, Colorado 80227</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Delmas, Pierre D" sort="Delmas, Pierre D" uniqKey="Delmas P" first="Pierre D." last="Delmas">Pierre D. Delmas</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Claude Bernard University Lyon 1</s1>
<s2>69372 Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Regional Bone Center Helen Hayes Hospital</s1>
<s2>West Haverstraw, New York 10993</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Cincinnati Bone Health and Osteoporosis Center</s1>
<s2>Cincinnati, Ohio 45219</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Luckey, Marjorie" sort="Luckey, Marjorie" uniqKey="Luckey M" first="Marjorie" last="Luckey">Marjorie Luckey</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>St. Barnabas Osteoporosis Center</s1>
<s2>Livingston, New Jersey 07039</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Adachi, Jonathan" sort="Adachi, Jonathan" uniqKey="Adachi J" first="Jonathan" last="Adachi">Jonathan Adachi</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>St. Joseph's Healthcare McMaster University</s1>
<s2>Hamilton, Ontario, L8S4L8</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Saag, Kenneth" sort="Saag, Kenneth" uniqKey="Saag K" first="Kenneth" last="Saag">Kenneth Saag</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama 35233</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, Pennsylvania 15213</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Seeman, Ego" sort="Seeman, Ego" uniqKey="Seeman E" first="Ego" last="Seeman">Ego Seeman</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Endocrinology Department Austin Health, University of Melbourne</s1>
<s2>Victoria 3010</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Bone Research Unit Leuven University, Department of Experimental Medicine</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Meeves, Suzanne" sort="Meeves, Suzanne" uniqKey="Meeves S" first="Suzanne" last="Meeves">Suzanne Meeves</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Sanofi-aventis</s1>
<s2>Bridgewater, New Jersey 08807</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lang, Thomas F" sort="Lang, Thomas F" uniqKey="Lang T" first="Thomas F." last="Lang">Thomas F. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Radiology Center for Molecular and Functional Imaging, University of California at San Francisco</s1>
<s2>San Francisco, California 94107</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bilezikian, John P" sort="Bilezikian, John P" uniqKey="Bilezikian J" first="John P." last="Bilezikian">John P. Bilezikian</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Endocrinology Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons</s1>
<s2>New York, New York 10021</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of clinical endocrinology and metabolism</title>
<title level="j" type="abbreviated">J. clin. endocrinol. metab.</title>
<idno type="ISSN">0021-972X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of clinical endocrinology and metabolism</title>
<title level="j" type="abbreviated">J. clin. endocrinol. metab.</title>
<idno type="ISSN">0021-972X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Alendronic acid</term>
<term>Antiosteoporotic</term>
<term>Antiresorptive agent</term>
<term>Early</term>
<term>Endocrinology</term>
<term>Female</term>
<term>Human</term>
<term>Metabolic diseases</term>
<term>Nutrition</term>
<term>Nutritional status</term>
<term>Obesity</term>
<term>Osteoporosis</term>
<term>Risedronic acid</term>
<term>Teriparatide</term>
<term>Treatment</term>
<term>Woman</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ostéoporose</term>
<term>Précoce</term>
<term>Homme</term>
<term>Tériparatide</term>
<term>Femelle</term>
<term>Femme</term>
<term>Acide alendronique</term>
<term>Adulte</term>
<term>Traitement</term>
<term>Acide risédronique</term>
<term>Endocrinologie</term>
<term>Maladie métabolique</term>
<term>Nutrition</term>
<term>Obésité</term>
<term>Antiostéoporotique</term>
<term>Antirésorptif</term>
<term>Etat nutritionnel</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Femme</term>
<term>Adulte</term>
<term>Nutrition</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. Methods: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early changes in bone turnover markers and 12-month areal and volumetric BMD. Results: In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean ± SE, 86.0 ± 5.6 vs. 61.2 ± 5.3 ng/ml, respectively; P < 0.001). Findings were similar for the other bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05). Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45). Teriparatide was well tolerated. Conclusion: This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0021-972X</s0>
</fA01>
<fA02 i1="01"><s0>JCEMAZ</s0>
</fA02>
<fA03 i2="1"><s0>J. clin. endocrinol. metab.</s0>
</fA03>
<fA05><s2>93</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MILLER (Paul D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DELMAS (Pierre D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LINDSAY (Robert)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WATTS (Nelson B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LUCKEY (Marjorie)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ADACHI (Jonathan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SAAG (Kenneth)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GREENSPAN (Susan L.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SEEMAN (Ego)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>BOONEN (Steven)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MEEVES (Suzanne)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LANG (Thomas F.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>BILEZIKIAN (John P.)</s1>
</fA11>
<fA14 i1="01"><s1>Colorado Center for Bone Research</s1>
<s2>Lakewood, Colorado 80227</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Claude Bernard University Lyon 1</s1>
<s2>69372 Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Regional Bone Center Helen Hayes Hospital</s1>
<s2>West Haverstraw, New York 10993</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>University of Cincinnati Bone Health and Osteoporosis Center</s1>
<s2>Cincinnati, Ohio 45219</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>St. Barnabas Osteoporosis Center</s1>
<s2>Livingston, New Jersey 07039</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>St. Joseph's Healthcare McMaster University</s1>
<s2>Hamilton, Ontario, L8S4L8</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama 35233</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, Pennsylvania 15213</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Endocrinology Department Austin Health, University of Melbourne</s1>
<s2>Victoria 3010</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Bone Research Unit Leuven University, Department of Experimental Medicine</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Sanofi-aventis</s1>
<s2>Bridgewater, New Jersey 08807</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Radiology Center for Molecular and Functional Imaging, University of California at San Francisco</s1>
<s2>San Francisco, California 94107</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Division of Endocrinology Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons</s1>
<s2>New York, New York 10021</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>3785-3793</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6022</s2>
<s5>354000184256870180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0499193</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Journal of clinical endocrinology and metabolism</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. Methods: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early changes in bone turnover markers and 12-month areal and volumetric BMD. Results: In the prior risedronate group, the N-terminal propeptide of type 1 collagen increase was significantly greater after 3 months of teriparatide than in the prior alendronate group (mean ± SE, 86.0 ± 5.6 vs. 61.2 ± 5.3 ng/ml, respectively; P < 0.001). Findings were similar for the other bone turnover markers. The changes in areal BMD and trabecular spine volumetric BMD were also greater in the prior risedronate group (P < 0.05). Early changes in bone turnover markers correlated with changes in trabecular spine volumetric BMD at 12 months (Spearman r = 0.45). Teriparatide was well tolerated. Conclusion: This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A16E</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A28</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B21</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Ostéoporose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Osteoporosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Osteoporosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Précoce</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Early</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Precoz</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tériparatide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Teriparatide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Teriparatida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Femelle</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Female</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hembra</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Femme</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Woman</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mujer</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Acide alendronique</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Alendronic acid</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Acido alendrónico</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Adulte</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Adult</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Adulto</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Acide risédronique</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Risedronic acid</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Acido risedrónico</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Endocrinologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Endocrinology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Endocrinología</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Nutrition</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Nutrition</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Nutrición</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Obésité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Obesity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Obesidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Antiostéoporotique</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antiosteoporotic</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Antiosteoporótico</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Antirésorptif</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Antiresorptive agent</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Antirresortivo</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Etat nutritionnel</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Nutritional status</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Estado nutricional</s0>
<s5>27</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Ostéoformateur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Osteoforming</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Osteoformador</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Bisphosphonates</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Bisphosphonates</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Bisfosfonatos</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Dérivé de l'acide diphosphonique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Diphosphonic acid derivatives</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Difosfonico ácido derivado</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble de la nutrition</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nutrition disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno nutricíon</s0>
<s5>41</s5>
</fC07>
<fN21><s1>329</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E11 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002E11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0499193
   |texte=   Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri